- In September 2024, Moffitt Cancer Center has partnered with AstraZeneca to fast-track the development of CAR T and TCR T cell therapies. AstraZeneca will gain priority access to Moffitt’s clinical expertise and collaborate closely with physician-scientists, boosting the investigation of innovative cell therapies and enhancing the company’s position in the growing immunotherapy market
- In November 2023, ProKidney Corp. has released positive interim data from its RMCL-002 Phase 2 study, supporting the advancement of its REACT (rilparencel) renal autologous cell therapy for diabetic CKD. This positions the company for late-stage development and has the potential to transform treatment for high-risk diabetic CKD patients, driving further growth and innovation for ProKidney.
